Explore the Latest Natalizumab Tenders on Tender Impulse - Your Trusted Global Tender Website
Are you searching for the latest Natalizumab Tenders from trusted sources across the globe? Tender Impulse is the go-to tender website for businesses seeking verified, timely updates on public tenders, government tenders and business tenders.
With real-time data and smart filters, you can find the most relevant Natalizumab Tenders issued by ministries, public sector organisations and international procurement agencies - whether you're an SME or a multinational.
All-in-One Platform for Natalizumab Tenders
- Requests for Proposals (RFPs) & Quotations (RFQs)
- General Procurement Notices (GPNs) & Expressions of Interest (EOIs)
- Prequalification documents, contract awards and amendments
Why Choose Tender Impulse?
- Custom email alerts tailored to your industry.
- Global coverage across 190+ countries and every major sector.
- Instant document access - specifications, BOQs and tender forms.
- Advanced filters by country, industry, deadline, value and procurement type.
Request a free live demo today and explore thousands of Natalizumab Tenders and beyond.
7611335Germany Pharmaceutical products Open house Arzneimittelrabattvertrge zum Wirkstoff Natalizumab iv Darreichungsform ATC L04AG03Country: GermanyDeadline31 Mar 20278905369Germany Pharmaceutical products Abschluss eines nicht exklusiven Rabattvertrages nach 130a Abs 8 SGB V zu Arzneimitteln mit dem Wirkstoff Natalizumab ATC-Code L04AG03Country: GermanyDeadline27 Jul 20279381460Germany Pharmaceutical products Open house Arzneimittelrabattvertrge zum Wirkstoff Natalizumab sc Darreichungsform ATC L04AG03Country: GermanyDeadline31 Aug 20279780704Germany Pharmaceutical products Open house Arzneimittelrabattvertrge Natalizumab in der Darreichungsform KonzzHersteInf-Lsg ATC L04AG03Country: GermanyDeadline03 Oct 20279814121Germany Pharmaceutical products Abschluss einer nicht-exklusiven Rabattvereinbarung nach 130a Abs 8 SGB V zum Wirkstoff Natalizumab ausschl in der Dafo IFK f d Zeit 011225 - 301Country: GermanyDeadline05 Oct 202710279890Germany Pharmaceutical products Open-House-Biologika-Rabattvertrge 2025-36 - Natalizumab Darreichungsform zur subkutanen InjektionCountry: GermanyDeadline31 Jan 202810281606Germany Pharmaceutical products Open-House-Biologika-Rabattvertrge 2025-35 - Natalizumab Darreichungsform zur intravensen AnwendungCountry: GermanyDeadline31 Jan 202810333798Open House Biologics Discount Agreements 2025-36 - Natalizumab (dosage form for subcutaneous injection)Country: GermanyDeadline31 Jan 202811966870Germany Pharmaceutical products Open-House-Biologika-Rabattvertrge 2026-04 - Natalizumab ivCountry: GermanyDeadline30 Apr 202813380422Medicines - Open house drug discount agreements for the active ingredient Natalizumab, s.c. Dosage form, ATC L04AG03Country: GermanyDeadline31 Aug 202713401682Suministro de Uroquinasa (DOE) y Natalizumab (DOE)Country: AndorraDeadline15 Sep 202613474465Medicines - Open house drug discount agreements for the active ingredient Natalizumab, s.c. Dosage form, ATC L04AG03Country: GermanyDeadline31 Aug 202713481596Medicines - Conclusion not excluding medicine discount agreement. according to Section 130a Paragraph 8 SGB V by means of an open house model for the active ingredient NatalizumabCountry: GermanyDeadline30 Nov 202613493273Open house drug discount agreements Natalizumab in the dosage form Konz.z.Herst.e.Inf.-Lsg. , ATC L04AG03Country: GermanyDeadline03 Oct 202713568467Medicines - Conclusion not excluding medicine discount agreement. according to Section 130a Paragraph 8 SGB V by means of an open house model for the active ingredient NatalizumabCountry: GermanyDeadline30 Nov 202613581541Medicines - Open house drug discount agreements for the active ingredient Natalizumab, s.c. Dosage form, ATC L04AG03Country: GermanyDeadline31 Aug 202713632585Open house drug discount agreements Natalizumab in the dosage form Konz.z.Herst.e.Inf.-Lsg. , ATC L04AG03Country: GermanyDeadline03 Oct 202713853361Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Natalizumab (ausschließlich Darreichungsform ILO), ATC L04AA23 für die Zeit 01.09.2026Country: GermanyDeadline04 Jul 202813996457Arzneimittel mit dem Wirkstoff Natalizumab (ATC: L04AG03)Country: GermanyDeadline30 Jul 2028
